Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein(a) levels by more than 90% for at least six months with a single injection in a phase 2 trial, reinforcing its ...

Amgen has reported encouraging mid-stage results for its olpasiran candidate for reducing lipoprotein(a) – a risk factor for atherosclerotic cardiovascular disease – and now plans to move ahead ...

Welcome to New Music Friday, your ultimate round-up of this week's single, album and home entertainment releases. Let's get stuck into this week's stacked albums slate. Hilary's re-imagined classics ...